Navigating the CDMO Market: Hurdles, Transformation & Opportunities

Information

This session was broadcast live on 18th May at 3pm CET. The on-demand version is now available to view for the duration of CPhI Discover.

After a tumultuous year, what are the key factors shaping the future of the CDMO market? This session will bring together industry stakeholders for an outlook on 2021 and beyond.

Discussion points:

CDMO market outlook, where do the most significant opportunities lies
What does technology and innovation look like in a post-COVID-19 world? Is sector consolidation set to continue?
Manufacturing vaccines at scale – what are the concerns from the CDMO side?
Onshoring API Manufacturing – can we expect more manufacturers to expand operations on home turf?

Samsung BiologicsSamsung Biologics is a fully integrated contract service provider offering development, manufacturing, and testing services, all from a single location. We provide highly tailored solutions to clients, while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals and the largest single site capacity, Samsung Biologics is a trusted CDMO partner of choice, and is uniquely able to provide seamless offerings from cell line development to final fill/finish as well as laboratory testing service.

Registered attendees

- Javier Aznarez

Business Development ManagerIdifarma

ARK

Abdul Rahman Khalifeh

Vice President - Client ServicesDe Facto Communications

Akshay Purohit

Sales ManagerWavelength Pharmaceuticals

Navigating the CDMO Market: Hurdles, Transformation & Opportunities

Information

Registered attendees

Log in

Log in